Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RD13-01 in r/r CD7+ T/NK Cell Malignancies
NCT04538599Phase 1Completed
- Start
- Sep 2020
- Primary completion
- Feb 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RD13-01 in t-cell acute lymphoblastic leukemia (T-ALL), precursor natural killer cell lymphoblastic leukemia/lymphoma, T cell lymphoblastic lymphoma (T-LBL) and 1 more. Primary endpoint: Dose-limiting toxicity at 4 weeks. Started Sep 2020; status: completed.
02
Drugs
RD13-01
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)precursor natural killer cell lymphoblastic leukemia/lymphomaT cell lymphoblastic lymphoma (T-LBL)T-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04538599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04538599.